Morningstar2mon
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listings for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets to accurately reflect the ...
The National Law Review22d
Federal Circuit Says Proper Orange Book-Listed Patent Must Claim Active Ingredient
You are responsible for reading, understanding, and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy ...
GlobalData on MSN1d
Eton secures US patent for diabetes insipidus treatment
Desmopressin is approved in various forms, but these do not meet the paediatric need for precise, titratable and small doses.
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the ...
Eton Pharmaceuticals granted new patent from USPTO
Eton Pharmaceuticals (ETON) announced that the United States Patent and Trademark Office has granted the company U.S. Patent No. 12,214,010, ...
Benzinga.com1mon
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
In the Notice Letter in January 2023, Teva stated that it intended to market a generic version of Firdapse before the expiration of multiple of Catalyst’s patents listed in the FDA Orange Book.